Literature DB >> 18991754

Suramin: clinical uses and structure-activity relationships.

Ross P McGeary1, Andrew J Bennett, Quoc B Tran, Kelly L Cosgrove, Benjamin P Ross.   

Abstract

Suramin is a polysulfonated polyaromatic symmetrical urea. It is currently used to treat African river blindness and African sleeping sickness. Suramin has also been extensively trialed recently to treat a number of other diseases, including many cancers. Here, we examine its modes of action and discuss its structure-activity relationships.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18991754     DOI： 10.2174/138955708786369573

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN： 1389-5575            Impact factor:   3.862


  45 in total

1.  Development of a comprehensive set of P2 receptor pharmacological research compounds.

Authors:  R A Felix; S Martin; S Pinion; D J Crawford
Journal:  Purinergic Signal       Date:  2011-11-04       Impact factor: 3.765

2.  The trypanocidal drug suramin and other trypan blue mimetics are inhibitors of pyruvate kinases and bind to the adenosine site.

Authors:  Hugh P Morgan; Iain W McNae; Matthew W Nowicki; Wenhe Zhong; Paul A M Michels; Douglas S Auld; Linda A Fothergill-Gilmore; Malcolm D Walkinshaw
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

3.  High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.

Authors:  Nathan P Coussens; Stephen C Kales; Mark J Henderson; Olivia W Lee; Kurumi Y Horiuchi; Yuren Wang; Qing Chen; Ekaterina Kuznetsova; Jianghong Wu; Sirisha Chakka; Dorian M Cheff; Ken Chih-Chien Cheng; Paul Shinn; Kyle R Brimacombe; Min Shen; Anton Simeonov; Madhu Lal-Nag; Haiching Ma; Ajit Jadhav; Matthew D Hall
Journal:  J Biol Chem       Date:  2018-06-26       Impact factor: 5.157

Review 4.  Using mitochondrial sirtuins as drug targets: disease implications and available compounds.

Authors:  Melanie Gertz; Clemens Steegborn
Journal:  Cell Mol Life Sci       Date:  2016-03-23       Impact factor: 9.261

Review 5.  Sirtuin activators and inhibitors: Promises, achievements, and challenges.

Authors:  Han Dai; David A Sinclair; James L Ellis; Clemens Steegborn
Journal:  Pharmacol Ther       Date:  2018-03-22       Impact factor: 12.310

6.  Towards a Treatment for Gulf War Illness: A Consensus Docking Approach.

Authors:  Rajeev Jaundoo; Jonathan Bohmann; Gloria E Gutierrez; Nancy Klimas; Gordon Broderick; Travis J A Craddock
Journal:  Mil Med       Date:  2020-01-07       Impact factor: 1.437

7.  Structure-based discovery of natural-product-like TNF-α inhibitors.

Authors:  Daniel Shiu-Hin Chan; Ho-Man Lee; Fang Yang; Chi-Ming Che; Catherine C L Wong; Ruben Abagyan; Chung-Hang Leung; Dik-Lung Ma
Journal:  Angew Chem Int Ed Engl       Date:  2010-03-16       Impact factor: 15.336

8.  Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles.

Authors:  Bei Cheng; Feng Gao; Erica Maissy; Peisheng Xu
Journal:  Acta Biomater       Date:  2018-12-05       Impact factor: 8.947

Review 9.  Borrelia burgdorferi glycosaminoglycan-binding proteins: a potential target for new therapeutics against Lyme disease.

Authors:  Yi-Pin Lin; Lingyun Li; Fuming Zhang; Robert J Linhardt
Journal:  Microbiology       Date:  2017-11-08       Impact factor: 2.777

10.  Combined treatment with paclitaxel and suramin prevents the development of metastasis by inhibiting metastatic colonization of circulating tumor cells.

Authors:  Arvind K Singla; Alla Bondareva; Frank R Jirik
Journal:  Clin Exp Metastasis       Date:  2014-06-26       Impact factor: 5.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.